Form 4: Abeona Therapeutics Director Donald A. Wuchterl Acquires Shares as Part of 2024 Board Grant

Director Donald A. Wuchterl acquired 11,797 shares of Abeona Therapeutics common stock on August 26, 2024, as part of the company's annual board grant.

Summary

• On August 26, 2024, Donald A. Wuchterl, a director of Abeona Therapeutics, acquired 11,797 shares of common stock.
• The acquisition was exempt under Rule 16b-3(d).
• These shares represent the remainder of the 2024 annual grant to the board of directors.
• This portion of the grant was withheld until all employees/management were allocated their shares and to enable onboarding of two new board members.
• The restricted stock will vest on August 26, 2025.
• Following the transaction, Wuchterl directly owns 114,511 shares of Abeona Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director, which is neither overtly positive nor negative.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This announcement is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency regarding the ownership of company stock by its directors.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates